This study will enroll approximately 800 patients with moderate to severe COPD in 2 subsets.
The 24-week subset will enroll approximately 400 patients randomized 1:1 ensifentrine (3 mg): placebo and the 48-week subset will enroll approximately 400 patients randomized 3:1 in order to minimize the number of patients assigned to placebo over 48 weeks.
The assessments in each subset are identical over the first 24 weeks. The 48-week subset will continue to assess long-term safety in this subset of patients.
Both studies will assess lung function, symptoms, and quality of life over 24 weeks. Safety and tolerability will be assessed over 24 or 48 weeks.
Participants will be compensated for study participation.
Condition | Chronic Obstructive Pulmonary Disease, COPD, COPD (Chronic Obstructive Pulmonary Disease) |
---|---|
Clinical Study Identifier | TX249241 |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.